Posted on October 11, 2017 by Sitemaster
So the discussion about how to use the data from the CHAARTED, STAMPEDE, and LATITUDE trials in the initial treatment of men with node-positive and metastatic hormone-sensitive and castration-resistant prostate cancer continues to be an issue of intense discussion among urologic and medical oncologists. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CHAARTED, hormone-sensitive, latitude, metastatic, mHSPC, nmHSPC, non-metastatic, STAMPEDE | 1 Comment »
Posted on September 13, 2017 by Sitemaster
Three months ago, James et al. presented the overall survival data from the most recently completed arm of the STAMPEDE trial at the annual meeting of the American Society of Clinical Oncology (ASCO). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: abirtaerone, ADT, hormone-sensitive, locally advanced, node-negative, node-positive, non-metastatic, outcome, STAMPEDE, survival | 7 Comments »
Posted on September 3, 2017 by Sitemaster
So about 3 years after the initial report of the results from the CHAARTED trial, 2 years after the initial report from the ADT + docetaxel arm of the STAMPEDE trial, and 3 months after the reports and publication of data from the LATITUDE trial and the ADT + abiraterone arm of the STAMPEDE trial, … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: hormone-resistant, hormone-sensistive, latitude, mCRPC, metastatic, mHSPC, STAMPEDE, Treatment | Leave a comment »
Posted on June 5, 2017 by Sitemaster
So one of the benefits of being at the annual ASCO meeting is that you get to talk to lots of medical oncologists who specialize in treating prostate cancer — if you are patient and polite. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, hromone-sensitive, latitude, metastatic, STAMPEDE | 6 Comments »
Posted on April 28, 2017 by Sitemaster
We have just heard from the STAMPEDE trial group in the UK that they will be presenting overall survival data from the “abiraterone comparison” arm of the STAMPEDE trial at the upcoming ASCO meeting this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, enzalutamide, STAMPEDE | 2 Comments »
Posted on January 5, 2016 by Sitemaster
In a poster presentation to be given at the upcoming Genitourinary Cancers Symposium in San Francisco later this week, data from the STAMPEDE trial in the UK appear to have demonstrated a result that few people seem to have expected. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", celecoxib, metastatic, outcome, STAMPEDE, Treatment, zoledronic acid | 4 Comments »
Posted on December 25, 2015 by Sitemaster
Back in May 2015, James et al. reported on the survival benefits associated with androgen deprivation therapy (ADT) + docetaxel-based chemotherapy compared to ADT alone as first-line therapy for treatment-naive men initially diagnosed with metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, chemotherapy, docetaxel, hormone-naive, metastatic, STAMPEDE | 4 Comments »
Posted on November 28, 2015 by Sitemaster
In a previous commentary, we mentioned the early top-line results of the STAMPEDE trial, which demonstrated a benefit to whole pelvic radiation and ADT for treatment of high-risk prostate cancer when positive pelvic lymph nodes have been detected. We now have some additional details. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", ADT, androgen, deprivation, radiation, STAMPEDE | 1 Comment »
Posted on May 14, 2015 by Sitemaster
So here’s the first important finding that will be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. Data from the UK’s STAMPEDE trial show a significant benefit from combining docetaxel-based chemotherapy with androgen deprivation therapy (ADT) in appropriately selected men. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen, deprivation, docetaxel, early, outcome, STAMPEDE, survival | 17 Comments »
Posted on December 3, 2014 by Sitemaster
Back in the late 1980s and early 1990s, the projected survival time for a man diagnosed with evident metastatic prostate cancer (then called D2 disease and now known as TxNxM1 disease) was about 18 to 36 months. Has that really changed in the past 25 years? … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, STAMPEDE, trial | 2 Comments »
Posted on October 31, 2014 by Sitemaster
Let’s say you are 58 years of age, in apparently excellent health for your age, when you get diagnosed with high-risk prostate cancer, based on a Gleason score of 4 + 4 = 8, a PSA level of 3.7, and a clinical stage of T1c, with 4/12 biopsy cores positive for cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", progressive, STAMPEDE, Treatment, trial | 6 Comments »
Posted on August 12, 2014 by Sitemaster
We have previously discussed, in some detail, the multi-arm, ongoing STAMPEDE trial in the UK and Switzerland, which is looking — in a comparative manner — at a whole series of treatment processes among men with advanced forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, enzalutamide, STAMPEDE | Leave a comment »
Posted on May 24, 2013 by Sitemaster
One of the more interesting sets of data on metastatic prostate cancer to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this year will be some of the very earliest data from the STAMPEDE trial, which we have discussed in some detail in an earlier post. … READ MORE …
Filed under: Uncategorized | Tagged: control, metastatic, outcome, STAMPEDE, survival | Leave a comment »
Posted on August 31, 2012 by Sitemaster
Most of the time, when we talk about clinical trials of drugs (or other treatments) for prostate cancer, we are talking about trials in which new treatment X is compared to standard (current) treatment Y or, if there is no standard, new treatment Z is compared to a placebo (a benign, “dummy” substitute). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: comparative, effectiveness, multi-arm, STAMPEDE, trial | 2 Comments »
Posted on November 18, 2008 by Sitemaster
Today’s news items include information about:
- The potential of spinal MRI in diagnosis of men at risk for spinal metastasis
- A review of data on use of PDE5 inhibitors to manage post-surgical erectile dysfunction
- A “flare” phenomenom associated with docetaxel therapy in some patients
- The current status of the STAMPEDE clinical trial … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: docetaxel, flare, MRI, PDE5 inhibitors, spinal metastasis, STAMPEDE | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 